2- (6- (5- chloro- 2- methoxyphenyl)- 4- oxo- 2- thioxo- 3,4- dihydropyrimidin- 1(2H)- yl)acetamide

a myeloperoxidase inhibitor for treatment of cardiovascular diseases; structure in first source

Also Known As:

PF-06282999

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Acetamides: 21
    - 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide: 3
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - Acetamides: 21
        2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide: 3

Experts

1.	Kalgutkar, Amit S: 3 articles (01/2019 - 11/2015)
2.	Buckbinder, Leonard: 2 articles (01/2019 - 11/2015)
3.	Ryder, Tim: 2 articles (02/2016 - 11/2015)
4.	Wolford, Angela: 2 articles (02/2016 - 11/2015)
5.	Bollinger, Eliza: 1 article (01/2019)
6.	Cortes, Christian: 1 article (01/2019)
7.	Coskran, Timothy M: 1 article (01/2019)
8.	Keliher, Edmund J: 1 article (01/2019)
9.	Kim, Albert M: 1 article (01/2019)
10.	Maresca, Kevin P: 1 article (01/2019)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 11/12/2015 - "Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases." 02/01/2016 - "The thiouracil derivative PF-06282999 [2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide] is an irreversible inactivator of myeloperoxidase and is currently in clinical trials for the potential treatment of cardiovascular diseases. "
2.	Atherosclerosis 01/01/2019 - "Here, utilizing PF-06282999, we investigated the role of MPO to regulate atherosclerotic lesion formation and composition in the Ldlr-/- mouse model of atherosclerosis. " 01/01/2019 - "To assess non-invasive monitoring of plaque inflammation, [18F]-Fluoro-deoxy-glucose (FDG) was administered to Ldlr-/- mice with established atherosclerosis that had been treated with clinically relevant doses of PF-06282999, and reduced FDG signal was observed in animals treated with a dose of PF-06282999 that corresponded with reduced necrotic core area. "
3.	Inflammation (Inflammations) 01/01/2019 - "To assess non-invasive monitoring of plaque inflammation, [18F]-Fluoro-deoxy-glucose (FDG) was administered to Ldlr-/- mice with established atherosclerosis that had been treated with clinically relevant doses of PF-06282999, and reduced FDG signal was observed in animals treated with a dose of PF-06282999 that corresponded with reduced necrotic core area. "

Related Drugs and Biologics

1.	Peroxidase (Myeloperoxidase)
2.	Thiouracil
3.	acetamide
4.	Glucose (Dextrose)